Keyphrases
Drug Interactions
100%
Cannabinoids
87%
Cannabidiol
82%
Δ9-tetrahydrocannabinol (Δ9-THC)
58%
Retrospective Cohort Study
58%
COVID-19
41%
Coronavirus Disease (COVID)
40%
Prescription Drugs
38%
Direct Oral Anticoagulants
38%
Healthcare Professionals
35%
Cannabis
33%
Warfarin
32%
Electronic Health Records
32%
Point-of-care Coagulation Testing
29%
United States
29%
Osteoporosis
29%
Fracture Rate
29%
Prasterone
29%
Rate Analysis
29%
Claims Database
29%
Pharmacotherapy
29%
Hydroxychloroquine
29%
Nested Case-control Study
29%
Remdesivir
29%
MarketScan
29%
Osteoporosis Care Gap
29%
Major Adverse Cardiovascular Events
29%
Cardiovascular Risk Reduction
29%
Glucose-lowering Drugs
29%
Pennsylvania
29%
Type 2 Diabetic Patients
29%
Taiwan
29%
Glycemic Control
29%
COVID-19 Pandemic
29%
Healthcare Workers' Perceptions
29%
Tetrahydrocannabinol
24%
Risk Factors
20%
Bisphosphonates
17%
Pharmacist
15%
Narrow Therapeutic Index
15%
Medical Laboratory
14%
Anticoagulants
14%
Rivaroxaban
14%
Apixaban
14%
Prescribing Information
14%
Penn State
14%
Alcohol
14%
Patient Characteristics
13%
Systemic Lupus Erythematosus
11%
Bone Mineral Density
11%
Pharmacology, Toxicology and Pharmaceutical Science
Drug-Drug Interaction
97%
Cannabinoid
58%
Dronabinol
58%
Dexamethasone
58%
Cohort Study
58%
Anticoagulant Agent
43%
Cannabis
38%
Cannabidiol
36%
Warfarin
32%
Prescription Medication
30%
Direct Oral Anticoagulant
30%
Nabiximols
29%
Bisphosphonic Acid Derivative
29%
Hydroxychloroquine
29%
Pharmacotherapy
29%
Atrial Fibrillation
29%
Remdesivir
29%
Case-Control Study
29%
Prasterone
29%
Parathyroid hormone[1-34]
29%
Abaloparatide
29%
Romosozumab
29%
Dehydroepiandrosterone Sulfate
29%
Diseases
29%
Pandemic
29%
Cross Sectional Study
29%
Therapeutic Window
15%
Systemic Lupus Erythematosus
14%
Thromboembolism
14%
SARS Coronavirus
14%
Community Pharmacy
14%
Infection
14%
Phenmetrazine
14%
Apixaban
11%
Rivaroxaban
11%
Glucocorticoid
11%
Cerebrovascular Accident
10%
Health Status
9%
Thrombosis
9%
Alendronic Acid
9%
Bleeding
9%
Hypochlorite Sodium
9%
Route of Administration
9%
Raloxifene
9%
Medical Cannabis
8%
Adverse Event
7%
Adverse Drug Reaction
7%
Medicine and Dentistry
Cannabinoid
58%
Cannabis
33%
Cannabidiol
31%
Nabiximols
29%
Glycemic Control
29%
Dronabinol
29%
Patient with Type 2 Diabetes
29%
Awareness
29%
Electronic Health Record
29%
Retrospective Cohort Study
29%
Health Care Provider
29%
Drug Interaction
29%
Systematic Review
29%
Cardiovascular Disease
29%
Tetrahydrocannabinol
24%
Prescription Medication
23%
Therapeutic Window
10%
Type 2 Diabetes
7%
Adverse Drug Reaction
7%
Adverse Event
7%
Abaloparatide
7%
Teriparatide
7%
Romosozumab
7%
Pharmacokinetics
7%
Hemoglobin A1c
5%